Known targets — ChEMBL curated mechanism
TUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TUBB8B
The experimentally established mechanism targets of Abt-751. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TUBB4A known ✓ | P04350 | 2/20 | 1.00 |
| ▸ | TUBB known ✓ | P07437 | 2/20 | 1.00 |
| ▸ | TUBB4B known ✓ | P68371 | 2/20 | 1.00 |
| ▸ | TUBB3 known ✓ | Q13509 | 2/20 | 1.00 |
| ▸ | TUBB2A known ✓ | Q13885 | 2/20 | 1.00 |
| ▸ | TUBB8 known ✓ | Q3ZCM7 | 2/20 | 1.00 |
| ▸ | TUBB6 known ✓ | Q9BUF5 | 2/20 | 1.00 |
| ▸ | TUBB2B known ✓ | Q9BVA1 | 2/20 | 1.00 |
| ▸ | TUBB1 known ✓ | Q9H4B7 | 2/20 | 1.00 |
| ▸ | TUBA3C | P0DPH7 | 2/20 | 1.00 |
| ▸ | TUBA1B | P68363 | 2/20 | 1.00 |
| ▸ | TUBA4A | P68366 | 2/20 | 1.00 |
| ▸ | TUBA3E | Q6PEY2 | 2/20 | 1.00 |
| ▸ | TUBA1A | Q71U36 | 2/20 | 1.00 |
| ▸ | TUBA1C | Q9BQE3 | 2/20 | 1.00 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.58 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.58 |
| ▸ | HTT | P42858 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Abt-751 SCHEMBL5023335 | 1.00 | TUBB4A (1.00) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL8622853 | 1.00 | TUBB4A (1.00) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| Abt-751 SCHEMBL111645 | 1.00 | TUBB4A (1.00) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| Abt-751 SCHEMBL5016878 | 0.99 | TUBB4A (0.98) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| Abt-751 SCHEMBL5016898 | 0.96 | TUBB4A (0.92) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL8625702 | 0.94 | TUBB4A (0.89) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL8624355 | 0.91 | TUBB4A (0.82) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL8629330 | 0.90 | TUBB4A (0.81) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL8623536 | 0.90 | TUBB4A (0.81) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL5692592 | 0.89 | TUBB4A (0.80) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1117 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260048022-A1 | ENDOTHELIAL DAMAGE AND NANOPARTICLE TARGETING: COMPOSITIONS, PROCESSES, USES | NANOPROBES INC (US) | 2026-02-19 | — | — | US | claimed |
| US-12551471-B2 | ABT-751 and ionizing radiation | Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis (NL) | 2026-02-17 | — | — | US | claimed |
| EP-4615576-A1 | CELLS BEING HIGHLY ENRICHED IN SASP FACTORS, AND COMPOSITION COMPRISING SAID CELLS | Evomedis GmbH (AT) | 2025-09-17 | — | — | EP | claimed |
| EP-4313156-B1 | DISULFIDE-BASED PRODRUG COMPOUNDS | UNIV MUENCHEN LUDWIG MAXIMILIANS (DE) | 2025-08-06 | — | — | EP | claimed |
| WO-2025151443-A1 | ENDOXIFEN FOR TREATMENT OF RARE CANCERS | ATOSSA THERAPEUTICS, INC. (US) | 2025-07-17 | — | — | WO | claimed |
| EP-4525834-A1 | ENDOTHELIAL DAMAGE AND NANOPARTICLE TARGETING: COMPOSITIONS, PROCESSES, USES | Nanoprobes, Inc. (US) | 2025-03-26 | — | — | EP | claimed |
| EP-4093398-B1 | ABT-751 AND IONIZING RADIATION FOR USE IN TREATING A BRAIN TUMOR | STICHTING HET NEDERLANDS KANKER INST ANTONI VAN LEEUWENHOEK ZIEKENHUIS (NL) | 2025-03-05 | — | — | EP | claimed |
| US-20250043285-A1 | Mammalian ATG8 Proteins and ATG9A Direct Sealing of Autophagosomal Membranes | UNM RAINFOREST INNOVATIONS (US) | 2025-02-06 | — | — | US | claimed |
| EP-4479042-A1 | CANCER TREATMENT BY COMBINED INHIBITION OF POLO-LIKE KINASE AND MICROTUBULE POLYMERIZATION | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2024-12-25 | — | — | EP | claimed |
| US-20240207414-A1 | DISULFIDE-BASED PRODRUG COMPOUND | LUDWIG-MAXIMILIANS-UNIVERSITAT MUNCHEN (DE) | 2024-06-27 | — | — | US | claimed |
| EP-4150075-A2 | COMPOSITIONS, SYSTEMS, AND METHODS FOR GENERATING GENE-EDITED CELLS | CELLSCRIPT, LLC (US) | 2023-03-22 | — | — | EP | claimed |
| US-20230070047-A1 | METHOD TO ENHANCE GENE EDITING | REGENTS OF THE UNIVERSITY OF MINNESOTA | 2023-03-09 | — | — | US | claimed |
| US-20230061353-A1 | ABT-751 AND IONIZING RADIATION | Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis (NL) | 2023-03-02 | — | — | US | claimed |
| WO-2023012707-A1 | ELECTRODE ASSEMBLY FOR APPLYING TUMOR TREATING FIELDS (TTFIELDS) WITH A SHEET OF ANISOTROPIC MATERIAL | NOVOCURE GMBH (CH) | 2023-02-09 | — | — | WO | claimed |
| EP-4093398-A1 | ABT-751 AND IONIZING RADIATION | Stichting Het Nederlands Kanker Instituut- Antoni van Leeuwenhoek Ziekenhuis (NL) | 2022-11-30 | — | — | EP | claimed |
| WO-2022214598-A1 | DICHALCOGENIDE PRODRUGS | LUDWIG-MAXIMILIANS-UNIVERSITÄT MÜNCHEN (DE) | 2022-10-13 | — | — | WO | claimed |
| EP-4071148-A1 | DICHALCOGENIDE PRODRUGS | Ludwig-Maximilians-Universität München (DE) | 2022-10-12 | — | — | EP | claimed |
| WO-2022200347-A1 | DISULFIDE-BASED PRODRUG COMPOUNDS | LUDWIG-MAXIMILIANS-UNIVERSITÄT MÜNCHEN (DE) | 2022-09-29 | — | — | WO | claimed |
| EP-4062942-A1 | DISULFIDE-BASED PRODRUG COMPOUNDS | Ludwig-Maximilians-Universität München (DE) | 2022-09-28 | — | — | EP | claimed |
| WO-2022112596-A1 | USE OF AMINOQUINOLINE COMPOUNDS FOR HIGHER GENE INTEGRATION | CELLECTIS SA (FR) | 2022-06-02 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260048022-A1 | ENDOTHELIAL DAMAGE AND NANOPARTICLE TARGETING: COMPOSITIONS, PROCESSES, USES | VEGFA, FLT1, FLT4 | TUBB4A 948/4885TUBB 1057/4885TUBB4B 1154/4885 |
| US-20240207414-A1 | DISULFIDE-BASED PRODRUG COMPOUND | CBS, MSR1, P4HB | TUBB4A 2646/4885TUBB 2338/4885TUBB4B 2062/4885 |
| US-20230061353-A1 | ABT-751 AND IONIZING RADIATION | BID, BIRC5, BAK1 | TUBB4A 1553/4885TUBB 597/4885TUBB4B 1589/4885 |
| US-20250043285-A1 | Mammalian ATG8 Proteins and ATG9A Direct Sealing of Autophagosomal Membranes | ATG7, BECN1, ATG4A | TUBB4A 320/4885TUBB 249/4885TUBB4B 504/4885 |
| US-12551471-B2 | ABT-751 and ionizing radiation | BID, MKI67, BAK1 | TUBB4A 2575/4885TUBB 1702/4885TUBB4B 2864/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.